BML Capital Management LLC Invests $2.43 Million in Connect Biopharma Holdings Limited (NASDAQ:CNTB)

BML Capital Management LLC purchased a new position in shares of Connect Biopharma Holdings Limited (NASDAQ:CNTB - Free Report) in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund purchased 2,061,438 shares of the company's stock, valued at approximately $2,432,000. Connect Biopharma comprises approximately 1.8% of BML Capital Management LLC's holdings, making the stock its 13th biggest position. BML Capital Management LLC owned approximately 3.74% of Connect Biopharma at the end of the most recent quarter.

Analysts Set New Price Targets

Separately, HC Wainwright boosted their target price on shares of Connect Biopharma from $7.00 to $8.00 and gave the company a "buy" rating in a research note on Wednesday, April 17th.

Connect Biopharma Trading Down 1.4 %

CNTB stock traded down $0.02 during trading on Wednesday, hitting $1.37. The stock had a trading volume of 41,055 shares, compared to its average volume of 145,551. The company's 50 day moving average price is $1.45 and its two-hundred day moving average price is $1.28. Connect Biopharma Holdings Limited has a 1-year low of $0.53 and a 1-year high of $2.84.

Connect Biopharma Company Profile

Connect Biopharma Holdings Limited, a clinical-stage biopharmaceutical company, focuses on developing therapies to treat T cell-driven inflammatory diseases. The company is building a pipeline of small molecules and antibodies using functional T cell assays to screen and discover potent product candidates against validated immune targets.